JP Morgan Reinstates Neutral on Agios Pharmaceuticals, Announces $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero has reinstated a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and announced a price target of $46.
June 13, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Tessa Romero has reinstated a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and set a price target of $46.
The Neutral rating suggests that JP Morgan does not see significant upside or downside in the short term for Agios Pharmaceuticals. The $46 price target provides a benchmark for investors, but the neutral stance indicates a balanced view on the stock's potential movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100